Century Therapeutics (IPSC) Cash & Equivalents (2020 - 2026)

Century Therapeutics (IPSC) has reported Cash & Equivalents for 7 consecutive years, with $51.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents fell 1.58% year-over-year to $51.0 million; the TTM figure through Mar 2026 stood at $51.0 million (down 1.58% YoY), while the FY2025 annual figure was $113.3 million, up 93.86% from the prior year.
• Cash & Equivalents declined to $51.0 million in Q1 2026 per IPSC's latest filing, from $113.3 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $126.0 million in Q1 2022 and bottomed at $41.5 million in Q2 2024.
• Historically, Cash & Equivalents has averaged $71.5 million across 5 years, with a median of $56.9 million in 2025.
• Annual changes were most pronounced in 2022 — Cash & Equivalents slumped 58.58% — and 2025, when it soared 93.86%.
• Century Therapeutics' Cash & Equivalents stood at $84.3 million in 2022, then tumbled by 43.84% to $47.3 million in 2023, then increased by 23.49% to $58.4 million in 2024, then jumped by 93.86% to $113.3 million in 2025, then slumped by 54.94% to $51.0 million in 2026.
• Business Quant data shows IPSC's Cash & Equivalents at $51.0 million in Q1 2026, $113.3 million in Q4 2025, and $55.5 million in Q3 2025.